Neuropathic pain-attenuating potential of aliskiren in chronic constriction injury model in rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 14, Issue 2, 2013, Pages 116-123

  Kukkar, Ankesh ^a   Singh, Nirmal ^a   Jaggi, Amteshwar S ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

aliskiren; Chronic constriction injury; inflammation; neuropathic pain; sciatic nerve ligation

Indexed keywords

ALISKIREN; TUMOR NECROSIS FACTOR ALPHA;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC CONSTRICTION INJURY; CONTROLLED STUDY; FEMALE; HYPERALGESIA; INJURY; MALE; NEUROPATHIC PAIN; NONHUMAN; RAT; SCIATIC NERVE;

ALISKIREN; CHRONIC CONSTRICTION INJURY; INFLAMMATION; NEUROPATHIC PAIN; SCIATIC NERVE LIGATION;

AMIDES; ANIMALS; CONSTRICTION; DISEASE MODELS, ANIMAL; FEMALE; FUMARATES; HYPERALGESIA; MALE; NEURALGIA; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877796637     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312460899     Document Type: Article

References (40)

1. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002 ; 18: 350-354 (Pubitemid 35291575)
2. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J. Renin Angiotensin Aldosterone Syst. 2006 ; 7: 3-14 (Pubitemid 43891239)
3. Simões E Silva AC, Flynn JT. The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. Pediatr Nephrol. 2012 ; 27: 1835-1845
4. Fukami K, Yamagishi S, Ueda S, et al. Role of AGEs in diabetic nephropathy. Curr Pharm Des. 2008 ; 14: 946-952 (Pubitemid 351753281)
5. Sata M, Fukuda D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J. Med Invest. 2010 ; 57: 12-25
6. Stiefel P, Vallejo-Vaz AJ, García-Morillo S, et al. Role of the renin-angiotensin system and aldosterone on cardiometabolic syndrome. Int J Hypertens. 2011 ;: 685238
7. Kurihara T, Ozawa Y, Ishida S, et al. Renin angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction. Int J Inflam. 2012 ;: 581695
8. Oruc N, Ozutemiz O, Nart D, et al. Inhibition of renin-angiotensin system in experimental acute pancreatitis in rats: a new therapeutic target?. Exp Toxicol Pathol. 2010 ; 62: 353-360
9. Tronvik E, Stovner LJ, Schrader H, et al. Involvement of the renin-angiotensin system in migraine. J Hypertens Suppl. 2006 ; 24: S139 - S143
10. Wood JM, Cumin F, Maibaum J. Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol Ther. 1994 ; 61: 325-344 (Pubitemid 24207703)
11. Lu H, Rateri DL, Feldman DL, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008 ; 118: 984-993 (Pubitemid 351364606)
12. Campos LA, Bader M, Baltatu OC. Brain renin-angiotensin system in hypertension, cardiac hypertrophy, and heart failure. Front Physiol. 2011 ; 2: 1-5
13. Ino J, Kojima C, Osaka M, et al. Dynamic observation of mechanically injured mouse femoral artery reveals an anti-inflammatory effect of renin inhibitor. Arterioscler Thromb Vasc Biol. 2009 ; 29: 1858-1863
14. Jaggi AS, Singh N. Differential effect of spironolactone in chronic constriction injury and vincristine-induced neuropathic pain in rats. Eur J Pharmacol. 2010 ; 648: 102-109
15. Jaggi AS, Singh N. Exploring the potential of telmisartan in chronic constriction injury-induced neuropathic pain in rats. Eur J Pharmacol. 2011 ; 667: 215-221
16. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1998 ; 33: 87-107
17. Maves TJ, Pechman PS, Gebhart GF, et al. Possible chemical contribution from chromic gut sutures produces disorders of pain sensation like those seen in man. Pain. 1993 ; 54: 57-69 (Pubitemid 23200572)
18. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincritine-induced painful peripheral neuropathy. Pain. 2004 ; 109: 150-161 (Pubitemid 38479781)
19. Erichsen HK, Blackburn-Munro G. Pharmacological characterization of the spared nerve injury model of neuropathic pain. Pain. 2002 ; 98: 151-161 (Pubitemid 34722477)
20. Jain V, Jaggi AS, Singh N. Ameliorative potential of rosiglitazone in tibial and sural nerve transection-induced painful neuropathy in rats. Pharmacol Res. 2009 ; 59: 385-392
21. Chaplan SR, Bach FW, Pogrel JW, et al. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994 ; 53: 55-63 (Pubitemid 24238751)
22. Lowry OH, Rosenbrough NJ, Farr AL, et al. Protein measurement with folin phenol reagent. J Biol Chem. 1951 ; 193: 265-275
23. Jaggi AS, Jain V, Singh N. Animal models of neuropathic pain. Fundam Clin Pharmacol. 2011 ; 25: 1-28
24. Jin Y, Sato J, Yamazaki M, et al. Changes in cardiovascular parameters and plasma norepinephrine level in rats after chronic constriction injury on the sciatic nerve. Pain. 2008 ; 135: 221-231 (Pubitemid 351324022)
25. Takai S, Song K, Tanaka T, et al. Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Life Sci. 1996 ; 59: PL331 - PL336
26. Camarda R, Monastero R, Mannino M, et al. Enalapril prophylaxis for migraine with aura. Headache. 2003 ; 43: 170 (Pubitemid 36188450)
27. Nandha R, Singh H. Renin angiotensin system: a novel target for migraine prophylaxis. Indian J Pharmacol. 2012 ; 44: 157-160
28. Schuh-Hofer S, Flach U, Meisel A, et al. Efficacy of lisinopril in migraine prophylaxis-an open label study. Eur J Neurol. 2007 ; 14: 701-703 (Pubitemid 46849050)
29. Gales BJ, Bailey EK, Reed AN, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother. 2010 ; 44: 360-366
30. Ceyhan GO, Michalski CW, Demir I, et al. Pancreatic pain. Best Pract Res Clin Gastroenterol. 2008 ; 22: 31-44
31. Demir IE, Tieftrunk E, Maak M, et al. Pain mechanisms in chronic pancreatitis: of a master and his fire. Langenbecks Arch Surg. 2011 ; 396: 151-160
32. Leung L, Cahill CM. TNF-alpha and neuropathic pain-a review. J Neuroinflammation. 2010 ; 7: 1-11
33. Higashikuni Y, Takaoka M, Iwata H, et al. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice. Hypertens Res. 2012 ; 35: 62-69
34. Del Fiorentino A, Cianchetti S, Celi A. Aliskiren, a renin inhibitor, downregulates TNF-alpha-induced tissue factor expression in HUVECS. J Renin Angiotensin Aldosterone Syst. 2010 ; 11: 243-247
35. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit. 2005 ; 11: RA194 - RA205
36. Kitazono T, Padgett RC, Armstrong ML, et al. Evidence that angiotensin II is present in human monocytes. Circulation. 1995 ; 91: 1129-1134
37. Potter DD, Sobey CG, Tompkins PK, et al. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation. 1998 ; 98: 800-807 (Pubitemid 28391846)
38. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008 ; 52: 130-136
39. Matavelli LC, Huang J, Siragy HM. (Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin Exp Pharmacol Physiol. 2010 ; 37: 277-282
40. Schmerbach K, Pfab T, Zhao Y, et al. Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes. PLoS One. 2010 ; 5: e15052